Baird Remains Buyers Of Gilead Before Earnings Release
In a report Thursday morning, analysts at Baird stated that they remain buyers of Gilead Sciences, Inc. (NASDAQ: GILD) before the company's fourth quarter earnings call next Tuesday, February 3.
Investors have been concerned that Gilead might disappoint after pricing concerns in the Hep C market.
"We expect Gilead's HCV franchise to return to form to close out 2014 after approval of Harvoni early on in the quarter has reversed the secondary warehousing effect of HCV patients. Our prescription trend analysis throughout the quarter indicates Sovaldi and Harvoni sales in the U.S. alone of $1.2B and $2.0B, respectively," they wrote.
They stated: "We don't expect to get definitive read-through on the actual magnitude of discounts until next quarter's update but we believe Gilead's discount is likely trending towards 25%."
The consensus fourth quarter EPS estimate is expected to be $2.17, however Baird analysts estimate $2.28 EPS.
If the fourth quarter EPS comes in at $2.28, that would put Gilead at $7.90 EPS for 2014.
The firm rates Gilead at an Outperform and has a $126 price target.
Latest Ratings for GILD
|Nov 2016||Stifel Nicolaus||Initiates Coverage On||Buy|
|Nov 2016||Mizuho||Initiates Coverage On||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.